These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29808267)

  • 41. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High C-reactive protein levels are associated with depressive symptoms in schizophrenia.
    Faugere M; Micoulaud-Franchi JA; Faget-Agius C; Lançon C; Cermolacce M; Richieri R
    J Affect Disord; 2018 Jan; 225():671-675. PubMed ID: 28917193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.
    Ciapparelli A; Dell'Osso L; Bandettini di Poggio A; Carmassi C; Cecconi D; Fenzi M; Chiavacci MC; Bottai M; Ramacciotti CE; Cassano GB
    J Clin Psychiatry; 2003 Apr; 64(4):451-8. PubMed ID: 12716249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.
    Freitas R; Dos Santos B; Altamura C; Bernasconi C; Corral R; Evans J; Malla A; Krebs MO; Nordstroem AL; Zink M; Haro JM; Elkis H
    Psychiatry Res; 2019 Jun; 276():210-217. PubMed ID: 31108345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
    Fond G; Boyer L; Berna F; Godin O; Bulzacka E; Andrianarisoa M; Brunel L; Aouizerate B; Capdevielle D; Chereau I; Coulon N; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Schürhoff F; Llorca PM;
    Br J Psychiatry; 2018 Aug; 213(2):464-470. PubMed ID: 29871707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?
    Spangaro M; Martini F; Bechi M; Buonocore M; Agostoni G; Cocchi F; Sapienza J; Bosia M; Cavallaro R
    J Psychiatr Res; 2021 Sep; 141():346-352. PubMed ID: 34304039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia.
    Fond G; Garosi A; Faugere M; Campion JY; Lancon C; Boyer L; Richieri R; Guedj E
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):905-912. PubMed ID: 34405275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.
    Rey R; D'Amato T; Boyer L; Brunel L; Aouizerate B; Berna F; Capdevielle D; Chereau I; Chesnoy-Servanin G; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lancon C; Mallet J; Misdrahi D; Passerieux C; Schandrin A; Schürhoff F; Urbach M; Vidailhet P; Llorca PM; Fond G;
    Eur Arch Psychiatry Clin Neurosci; 2017 Sep; 267(6):567-577. PubMed ID: 28389889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort.
    Sunhary de Verville PL; Etchecopar-Etchart D; Richieri R; Godin O; Schürhoff F; Berna F; Aouizerate B; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Leignier S; Mallet J; Misdrahi D; Passerieux C; Pignon B; Rey R; Urbach M; Vidailhet P; Leboyer M; Llorca PM; Lançon C; Boyer L; Fond G;
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110275. PubMed ID: 33582207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current (but not ex) cigarette smoking is associated with worse cognitive performances in schizophrenia: results from the FACE-SZ cohort.
    Mallet J; Godin O; Dansou Y; Mazer N; Scognamiglio C; Berna F; Boyer L; Capdevielle D; Chéreau I; D'Amato T; Dubreucq J; Fond G; Leigner S; Llorca PM; Misdrahi D; Passerieux C; Rey R; Pignon B; Urbach M; Schorr B; Schürhoff F; Yann LS; Dubertret C;
    Psychol Med; 2023 Aug; 53(11):5279-5290. PubMed ID: 36073848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review.
    Fond G; Lançon C; Auquier P; Boyer L
    Front Psychiatry; 2018; 9():392. PubMed ID: 30190688
    [No Abstract]   [Full Text] [Related]  

  • 55. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine.
    Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E
    Nord J Psychiatry; 2017 Feb; 71(2):89-95. PubMed ID: 27658459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones.
    Iasevoli F; Giordano S; Balletta R; Latte G; Formato MV; Prinzivalli E; De Berardis D; Tomasetti C; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():34-48. PubMed ID: 26320028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of smoked cannabis with treatment resistance in schizophrenia.
    Arsalan A; Iqbal Z; Tariq M; Ayonrinde O; Vincent JB; Ayub M
    Psychiatry Res; 2019 Aug; 278():242-247. PubMed ID: 31229838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.